“Cyborg” Bio-Incubator

Cyborg will stimulate therapeutic innovation to help invent tomorrow’s regenerative medicine and biotherapies.

A startup incubator specializing in biotechnologies

"Cyborg” is an incubator for startups specializing in biotechnologies, with ties to the Montpellier CHU’s Institute of Regenerative Medicine and Biotherapies (IRMB). These startups benefit from a top-quality shared production and transposition platform for biotherapies, drugs, regenerative medicine, and innovative therapies. The goal is to support the emergence of projects involving innovative therapies and their clinical approvals. The project seeks to stimulate therapeutic innovation by concentrating the necessary public and private resources, and by combining cellular engineering based on stem cells, materials, and robotics to create the regenerative medicine of tomorrow. It also meets a specific need that is not currently covered in the development chain for biotherapeutic drugs.

Implementing the Cyborg project will also strengthen Montpellier’s position in the biotechnology field. This is a major strategic opportunity to establish a position in an emerging high-potential market, as well as to create jobs with high value-added in the region. In the medium-term, it is also an important issue for patients who, today, frequently find themselves in a situation without any alternative therapeutic solution. To make this project a reality, a property development project of approximately 800 m² will need to be completed, extending the Montpellier CHU’s current IRMB facility, which is already operating at full capacity.

Inaugurated on November 7, 2018, the incubator is already home for eight startups working with biotechnologies and innovative therapies.

Institute of Regenerative Medicine and Biotherapies

IRMB unites scientists and medical expertise to focus on regenerative medicine and innovative immunotherapies. The institute associates Montpellier CHU, INSERM, and University of Montpellier (UM).
 
It comprises a research center, biotechnology companies, scientists, university hospital doctors, national organizations, and coordination for three Horizon 2020 European projects, enabling the development of research and innovation on adult stem cells, iPS (induced pluripotent stem cells) reprogramming, and new immunotherapies.